首页> 美国卫生研究院文献>Oncology Letters >Differential expression of the Notch1 receptor and its ligands Dll1 Dll3 and Dll4 in distinct human pituitary adenoma subtypes
【2h】

Differential expression of the Notch1 receptor and its ligands Dll1 Dll3 and Dll4 in distinct human pituitary adenoma subtypes

机译:Notch1受体及其配体Dll1Dll3和Dll4在不同的人垂体腺瘤亚型中的差异表达

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Pituitary adenoma (PA) is a common type of benign tumor of the pituitary gland that is characterized by specific signs and symptoms, primarily associated with hypersecretion of pituitary glycoprotein hormones (thyroid-stimulating, growth and adrenocorticotrophic hormones, and prolactin). Surgery is the first-line treatment, although postoperative residual tissues/cells and subsequent recurrence remain notable complications. Gene therapy is an effective approach for treatment, as previous studies have demonstrated that the Notch signaling pathway participates in the pathogenesis of PA. The focus of the present study was on the associations between the expression of the Notch1 receptor and its ligands δ-like canonical Notch ligand (Dll) 1, Dll3 and Dll4 in patients with PA. Using reverse transcription-quantitative polymerase chain reaction and western blot analyses, to the best of our knowledge, this is the first study to provide a description of the differential expression of the Notch1 receptor and its ligands Dll1, Dll3, and Dll4 in various types of human PA at the mRNA and protein levels. The results of the present study demonstrated that Notch1 protein expression was positively correlated with Dll4 protein expression, but negatively correlated with Dll3 protein expression, indicating synergistic effects between the Notch1 receptor and Dll4 ligand. Furthermore, the Dll3 ligand may be an inhibitor of the Notch1 receptor, indicating an antagonistic association between Notch1 and the Dll3 ligand. These results have identified a potential target for the treatment of patients with PA.
机译:垂体腺瘤(PA)是垂体良性肿瘤的一种常见类型,其特征是特定的体征和症状,主要与垂体糖蛋白激素(促甲状腺激素,生长激素和促肾上腺皮质激素和催乳激素)分泌过多有关。手术是一线治疗,尽管术后残留的组织/细胞和随后的复发仍然是明显的并发症。基因治疗是一种有效的治疗方法,因为以前的研究表明,Notch信号通路参与了PA的发病机理。本研究的重点是在PA患者中Notch1受体的表达与其配体δ样经典Notch配体(Dll)1,Dll3和Dll4之间的关联。据我们所知,使用逆转录定量聚合酶链反应和蛋白质印迹分析,这是第一项描述Notch1受体及其配体Dll1,Dll3和Dll4在各种类型人PA的mRNA和蛋白质水平。本研究的结果表明Notch1蛋白表达与Dll4蛋白表达正相关,但与Dll3蛋白表达负相关,表明Notch1受体和Dll4配体之间具有协同作用。此外,Dll3配体可能是Notch1受体的抑制剂,表明Notch1和Dll3配体之间存在拮抗作用。这些结果确定了治疗PA患者的潜在靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号